Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunoprecise Antibodies Ltd (IPA)

Immunoprecise Antibodies Ltd (IPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration...

IPA : 1.2500 (-2.34%)
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a “Decision...

IPA : 1.2500 (-2.34%)
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly...

IPA : 1.2500 (-2.34%)
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the...

IPA : 1.2500 (-2.34%)
CNTG : 0.4400 (+4.76%)
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal...

IPA : 1.2500 (-2.34%)
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics...

IPA : 1.2500 (-2.34%)
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss...

IPA : 1.2500 (-2.34%)
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AXNX : 66.87 (+0.45%)
IPA : 1.2500 (-2.34%)
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SYNH : 42.98 (+0.02%)
IPA : 1.2500 (-2.34%)
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal...

IPA : 1.2500 (-2.34%)

Barchart Exclusives

Down 12% from Highs, Should You Buy the Dip in This Dividend Aristocrat?
This prominent paint industry player has been raising dividends for more than four decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar